Bluejay Diagnostics, Inc.
BJDX$3M
Micro CapNASDAQSurgical & Medical Instruments & Apparatus🇺🇸North AmericaACTON
Drugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Aug 2026
Market Overview
Stock performance and key metrics
BJDX News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
Brelovitug 900 mg
Chronic Hepatitis D Infection
Brelovitug 300 mg
Chronic Hepatitis D Infection
Bulevirtide 2 mg and Brelovitug - 300 mg
Chronic Hepatitis D Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Brelovitug 900 mg | Phase 3 | Chronic Hepatitis D Infection | - | - |
Brelovitug 300 mg | Phase 3 | Chronic Hepatitis D Infection | - | - |
Bulevirtide 2 mg and Brelovitug - 300 mg | Phase 3 | Chronic Hepatitis D Infection | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply